About Us
Cimeio Therapeutics
We are an applied gene editing, cellular, and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs™ for patients with debilitating and life-threatening diseases. Our proprietary technology platform is based on the discovery of novel protein variants, which when inserted into cells allow them to preserve function while resisting depletion by a precisely paired immunotherapy. This technology has significant therapeutic potential, which we are using to develop curative treatments for patients with genetic diseases, hematologic malignancies, and severe autoimmune disorders.
Leadership

Thomas Fuchs
Chief Executive Officer

Tristan Imbert
Chief Financial Officer

Lukas Jeker, MD/PhD
Founder, SVP Gene Editing

Daniel Stark, PhD
Chief Manufacturing Officer

Stefanie Urlinger, PhD
SVP Biology

Thomas Winkler, MD
Chief Medical Officer

Thomas Fuchs
Chief Executive Officer

Tristan Imbert
Chief Financial Officer

Lukas Jeker, MD/PhD
SVP Gene Editing

Daniel Stark, PhD
Chief Manufacturing Officer

Stefanie Urlinger, PhD
SVP Biology

Thomas Winkler, MD
Chief Medical Officer
Scientific Advisory Board

Suneet Agarwal, MD, PhD
Assoc. Prof. Harvard Medical School

Jeff Bluestone, PhD
CEO, Sonoma Bio

Toni Cathomen, MD
Prof. University of Freiburg

Corey Cutler, MD, MPH, FRCPC
Assoc. Prof. Harvard Medical School

Fyodor Urnov, PhD, Chair
Prof. University of California Berkeley

Suneet Agarwal, MD, PhD

Jeff Bluestone, PhD

Toni Cathomen, MD

Corey Cutler, MD, MPH, FRCPC

Fyodor Urnov, PhD, Chair
Board of Directors

Lukas Jeker, MD/PhD
Founder, SVP Gene Editing

Markus Enzelberger, Ph.D.
Partner at Versant Ventures

Alexander Mayweg, Ph.D.
President of Ridgeline Discovery and Managing Director at Versant Ventures
Team

Marc Bigler

Thomas Burgold

Anna Camus

Valentin Do Sacramento

Laura Garcia Prat

Eva-Maria Grossjohann

Tanja Herrmann

Marcel Heugel

Andreja Knezevic

Mariah Kohlbrenner

Frank Lehmann

Emiel Ten Buren

Saniye Yumlu
